New England Deaconess Hospital Corporation

Abbott Laboratories Corporation

University of Tennessee Research Foundation

Edward Anthony Mascioli

Bruce R Bistrian

George L Blackburn

Vigen K Babayan

Stephen Joseph Demichele

Michael Donald Karlstad

R Armour Forse

There is disclosed structured lipid containing either a gamma-linolenic acid or a dihomogamma-linolenic acid residue, together with an n-3 fatty acid residue and a medium chain fatty acid residue on the same glycerol backbone. This structured lipid is particularly well adapted to the treatment of disease or stress states. The gamma-linolenic or dihomogamma-linolenic acid residues modify the prostanoid synthesis pathway, reducing the level of series '2' prostanoids and elevating the levels of series '1' and '3' prostanoids. The n-3 fatty acid residue enhances the level of series '1' prostanoids as well as increases the production of series '3' prostanoids. The medium chain fatty acid residues enhances the absorption of the structured lipid. There is also disclosed enteral and parenteral diets as well as nutritional supplements containing the structured lipids of the invention.

Structured lipid containing gamma-linolenic or dihomogamma-linolenic

Structured lipid containing gama-linolenic or dihogamma-linolenic fatty

Disclosed is a method of minimizing the effects of a catabolic illness in an individual by administering to the individual a diet which is controlled in the type of fatty acid intake. The diet comprises an oil rich in .omega.9 monounsaturated fatty acids, preferably oleic acid. Oils rich in monounsaturated fatty acids include olive oil, canola oil and high oleic acid safflower or high oleic acid sunflower oil. The diet can also be administered to an individual to minimize infection or to minimize the risk of infection in the individual. A dietary supplement useful in methods of the invention and a structured lipid are also disclosed.

Monounsaturated fat as dietary supplement to minimize the effects of

A new dietary supplement has been developed which yields the benefits of both .omega.3 oils and medium chain triglycerides for lipid nutrition. A structured lipid containing .omega.3 fatty acids and medium chain fatty acids is also disclosed.

Dietary supplement utilizing .omega.-3/medium chain trigylceride mixtures

Disclosed is a method of minimizing infection and minimizing the risks of infection in at risk animals and patients. A dietary supplement to accomplish this objective is also disclosed. The method includes the step of administering a diet rich in .omega.3 fatty acids, for example by adding a substantial proportion of fish oils to the diet. The dietary supplement is particularly well suited to patients receiving total parenteral nutrition. A parenteral diet or diet supplement containing a mixture of oils, one rich in .omega.3 fatty acids and the other rich in .omega.6 fatty acids is disclosed.

Parenteral dietary supplement and method of minimizing effects of

Disclosed is a method of minimizing infection and minimizing the risks of infection in at risk animals and patients. A dietary supplement to accomplish this objective is also disclosed. The method includes the step of administering a diet rich in .omega.3 fatty acids, for example by adding a substantial proportion of fish oils to the diet. The dietary supplement is particularly well suited to patients receiving total parenteral nutrition.

Growing community of inventors

Needham, MA, United States of America

Edward Anthony Mascioli